Compare Cigna Corp (CI) vs Docusign Inc (DOCU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Docusign Inc — how do they compare? Cigna Corp trades at $277.35 (market cap $73.56B), while Docusign Inc trades at $58.1 (market cap $11.33B). The key difference: Cigna Corp is far larger — about 6.5× Docusign Inc's market cap, and Cigna Corp pays a 2.24% dividend while Docusign Inc pays none. Which is the better fit depends on your goals.
| CI | DOCU | |
|---|---|---|
Market Cap | $73.56B | $11.33B |
Sector | Health | Technology |
52-Week High | $311.00 | $85.01 |
52-Week Low | $244.41 | $41.75 |
Enterprise Value | $98.27B | $10.70B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $278.15, showing slight daily weakness but maintaining a strong fundamental profile with consistent earnings beats. The stock appears undervalued with a P/E of 11.51 and P/S of 0.26, while technical indicators show bearish momentum near key support at $271. Recent Q2 2026 results exceeded expectations with EPS of $7.78 versus $7.60 estimates, driving management's raised full-year guidance.
Cigna presents a compelling value opportunity with analyst consensus pointing to 22% upside to the $338.90 price target. However, near-term technical pressure and competitive healthcare margins require monitoring. The company's stable dividend payments and institutional accumulation support long-term confidence despite current bearish technical signals.
DOCU trades at $57.82, down 3.05% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.09 exceeding the $0.994 estimate. Revenue growth remains steady, reaching $2.98B in 2025, while profitability improved significantly with a net income margin of 35.87%. Recent news highlights institutional trading activity and positive analyst coverage on growth prospects.
The outlook for DOCU is mixed; fundamentals show robust revenue growth and expanding margins, but valuation multiples like a P/E of 38.53 suggest premium pricing. Key risks include competitive pressures in e-signature software and reliance on subscription revenue. Analyst consensus is cautious with a hold-heavy rating, though the $55.40 price target implies limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
